IGA IMMUNE RESPONSE TO H PYLORI IN HUMAN FLUIDS

IGA 对人体体液中幽门螺杆菌的免疫反应

• 批准号: 2859208
• 负责人: KAREN M PAGE
• 金额: $ 10万
• 依托单位: DGI BIOTECHNOLOGIES, LLC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-08-21 至 1998-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2859208
• 关键词: Helicobacter; binding proteins; enzyme linked immunosorbent assay; human tissue; immunoglobulin A; method development; mucosal immunity; saliva; urine

The long term objective is to develop innovative commercial products for investigating the IgA immune response to Helicobacter pylori, a major causative agent of gastritis and duodenal and gastric ulcers. These products will be based on an ELISA incorporating Protein B, a highly specific and sensitive IgA binding protein to measure IgA to H. pylori in a variety of human fluids. They will be used to monitor the mucosal immune response to H. pylori vaccines and therapies and provide a means to monitor risk of gastric cancer and other diseases resulting from H. pylori infection. Protein B-based ELISAs will have many advantages over commercially available immunoassays for H. pylori. Protein B binds with a very high affinity for human IgA resulting in assays that are very sensitive and reproducible with low backgrounds. Specific objectives for Phase I are to develop an assay for quantitative measurement of serum IgA against H. pylori, develop saliva assays for secretory IgA to H. pylori as a measure of mucosal immune response and to investigate urine as a carrier of IgA to H. pylori. During Phase II, the assays will be precisely characterized and optimized, then validated in clinical studies and vaccine trials. PROPOSED COMMERCIAL APPLICATIONS: The Protein B-H. pylori ELISA for serum will be an innovative research tool to study the role of specific IgA as a biomarker for diseases such as gastric cancer. The technology can be extended beyond H. pylori to develop clinical biomarker assay products for other infectious diseases. The saliva assay has the potential to be used in the development of not only H. pylori vaccines, but also any vaccine that requires a mucosal immune response to be effective, such as HIV.

长期目标是开发创新的商业产品， 研究伊加免疫反应幽门螺杆菌，一个主要的 胃炎、十二指肠溃疡和胃溃疡的病原体。这些 产品将基于结合蛋白B的ELISA， 特异性和敏感性的伊加结合蛋白来测量伊加对H.幽门 在各种人体液体中。它们将用于监测粘膜 对H.幽门螺杆菌疫苗和疗法，并提供了一种手段， 监测H. 幽门感染基于蛋白B的ELISA将具有许多优点， 市售的H.幽门。蛋白质B与 对人伊加具有非常高的亲和力，导致测定非常 灵敏度高，重现性好，背景低。 第一阶段的具体目标是开发一种定量测定方法， 血清伊加抗H.幽门螺杆菌，开发唾液检测， 分泌型伊加至H.幽门螺杆菌作为粘膜免疫应答的量度， 探讨尿液作为伊加到H.幽门。在第二阶段， 这些检测将被精确地表征和优化，然后进行验证。 在临床研究和疫苗试验中。 拟议的商业应用： 蛋白质B-H血清pylori ELISA将是一项创新性的研究 研究特异性伊加作为疾病生物标志物的作用的工具， 是胃癌该技术可以扩展到H.幽门 开发用于其他传染病的临床生物标志物检测产品。 唾液检测有可能用于开发非 只有H.幽门螺杆菌疫苗，但也有任何疫苗，需要粘膜 免疫反应是有效的，如艾滋病毒。